Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Research Activity

Recent Publications

SGLT2 inhibitors

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study

Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study

SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem

Comment and response to: Dapagliflozin-do we need it registered for type 2 diabetes?

The emerging role of oxylipins in thrombosis and diabetes

Diabetes, antidiabetic drugs, and cancer: Separating background risk from iatrogenesis

Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer?

Ramadan: Type 2 diabetes and risk of hypoglycaemia

Visual vignette

Antiretroviral lipodystrophy of the forehead.

Collaboration designed to increase translation of diabetes research outcomes into clinical practice

Denosumab: Do we need another of the same?

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor Dapagliflozin

Consider insulin therapy to correct perioperative hyperglycemia in both diabetic and nondiabetic patients

Stop metformin before elective surgery or intravascular contrast dye study to decrease the risk of lactic acidosis

Subclinical hyperthyroidism: Current concepts and scintigraphic imaging

Exenatide once weekly in type 2 diabetes mellitus